Pfizer and BioNTech have applied for emergency use authorization of their Omicron-adapted COVID-19 vaccine in the United States as a booster dose for children aged 6 months through 4 years, the companies announced.
Although new COVID-19 cases in children, as measured by the AAP and the CHA, remained steady in recent months, data from the CDC suggest that weekly cases took a big jump in early January.